5% Dextrose Kit Injection

Adult administration

500 to 1000 mL is administered as an intravenous injection at a rate not exceeding 0.5 g/kg per hour of dextrose. An appropriate amount is used for the dissolution and dilution of the injectable medication. Adjustments should be made according to age and symptoms.

This medication contains dextrose for injection and requires caution during intravenous administration as it may increase the consumption of vitamin B1, potentially leading to severe deficiency. This medication should not be administered to specific patients, such as those with storage dehydration, fluid overload, hyperglycemia, acidosis, hypokalemia, hyperosmolar coma, and patients with glucose intolerance. Additionally, it is safe not to use this medication in patients with anuria, hepatic coma, patients with hypersensitivity to this medication, and patients with spinal or intracranial hemorrhage. It should be administered cautiously in patients with tendencies towards potassium, phosphate, and magnesium deficiency or in patients with hyponatremia, diabetes insipidus, renal failure, and heart failure, who require careful management. This medication can cause side effects such as electrolyte imbalance, fluid overload, and pulmonary edema when administered in large doses, so it should be used with careful adjustments to the dose and rate. Furthermore, in patients who have difficulty controlling blood sugar levels, hyperglycemia or renal damage may occur, requiring periodic monitoring of blood glucose and electrolyte levels. During pregnancy, safety for the fetus has not been established and should only be used when the potential benefits outweigh the risks, and care should be taken regarding blood sugar changes in the mother and newborn during administration. Newborns, especially preterm or low birth weight infants, are at higher risk for hypoglycemia or hyperglycemia and require close monitoring of blood sugar status. Elderly patients may have diminished physiological functions, so care should be exercised in their administration. In cases of excessive dosing, hyperglycemia may develop, necessitating insulin treatment. This medication is not recommended for administration by subcutaneous injection; it should be used immediately after opening, and any unused solution should be discarded. To prevent infection at the injection site, cleanliness should be maintained, and it is advisable to warm the solution to body temperature before use. When used in conjunction with other medications, potential chemical interactions and adverse reactions should be adequately considered and carefully observed. When used for hydration in dehydrated patients, it should be administered slowly, and appropriate procedures should be followed for the dissolution process. Finally, to reduce the risk of air embolism, continuous connection use should be avoided.

Serious side effects

Severe swelling (edema), severe rash associated with high fever, blisters, skin peeling, pain in mucous membranes of mouth/eyes, difficulty breathing or shortness of breath, asthma attacks, respiratory abnormalities with cough and fever, yellowing of skin or eyes (jaundice), extreme fatigue throughout the body, sudden and severe headache, thunderclap headache, seizures, confusion of consciousness, visual disturbances, paralysis, significantly reduced urine output, severe swelling throughout the body, elevated blood pressure.

Mild side effects

Hypokalemia, hyperosmolar coma, acidosis, dehydration, hyperosmolarity, polyuria with dextrose detection, fluid or solute overload, electrolyte imbalance, congestion, pulmonary edema, hyperglycemia, renal loss, fever, phlebitis, thrombosis, blood leakage, injection site pain, uremia, effect on insulin production, changes in blood glucose levels, serum electrolyte imbalances, ketonuria, changes in serum potassium and phosphate levels, increased risk of hypoglycemia and hyperglycemia.

This medication should be stored in a sealed container to prevent air ingress and should be kept at room temperature between 1 degree and 30 degrees Celsius. Proper storage will maintain the medication's effectiveness and prevent deterioration.

Appearance

A kit injection composed of a capsule part for powder injection and a colorless, transparent polypropylene container containing the solvent.

Package unit

100 milliliters/kit [x 10], 110 milliliters/kit [x 10], 250 milliliters/kit [x 10]